Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford BioMedica has received a favorable ruling in a US district court for the validity of its intellectual property which is licensed exclusively in the research field to Sigma-Aldrich.
Subscribe to our email newsletter
In his order US District Judge Charles Shaw concluded “that the constructions of the disputed terms and phrases proposed by plaintiff are correct.”
The lawsuit alleges that Open Biosystems infringes US patent nos 6,924,123 and 7,056,699 entitled Lentiviral LTR deleted vector that are owned by Oxford BioMedica and exclusively licensed to Sigma-Aldrich for research use.
Oxford BioMedica’s LentiVector system has broad applications in gene delivery and can be used to deliver shRNA-encoding DNA to cells to enable RNA Interference (RNAi) experiments.
David Smoller, president of research biotechnology business unit of Sigma-Aldrich, said: “We are gratified and very pleased that the Court has adopted Sigma’s and Oxford’s definitions of all disputed claim terms in this case. This order reinforces Sigma’s belief that the Oxford Biomedica patents are ‘core patents’ in the RNA-interference field, and validates Sigma’s decision to license these patents and make other significant investments in creating a comprehensive portfolio of intellectual property that allows our customers to use this extraordinary technology without fear of interference or unfair competition.”